## **Procedure description**
HCPCS code Q5128 describes the procedure for the injection of ranibizumab-eqrn (Cimerli), a biosimilar medication, specifically dosed at 0.1 mg. This code covers the administration of Cimerli biosimilar via intravitreal injection, which is an injection of a pharmacologic agent into the eye. This procedure is commonly used to treat several retinal conditions, including macular edema, proliferative diabetic retinopathy, retinal vein occlusion, diabetic macular edema, and age-related macular degeneration.
The effective date for using HCPCS Code Q5128 was April 1, 2023. The code is a vital part of coding information for providers billing for the administration of the ranibizumab eqrn Cimerli biosimilar. The billing is based on dosage units (0.1 mg per unit), consistent with the q51286/45–161 guidance. Providers need to document the procedure accurately to ensure proper reimbursement.
## **HCPCS code Q5128 documentation requirements**
When documenting the use of Cimerli biosimilar 0.1 mg (ranibizumab-eqrn), ensure the medical record includes the following key details for accuracy, compliance, and continuity of care:
- Clearly document the use of 0.1 mg ranibizumab-eqrn Cimerli biosimilar in the patient's medical record.
- Specify dosage and administration details.
- Record the indication for treatment, such as conditions like diabetic macular edema, age-related macular degeneration, retinal vein occlusion, or proliferative diabetic retinopathy.
- Include the date and time of the intravitreal injection procedure.
- Document the administration technique and any relevant procedural notes.
- Note any patient reactions or adverse events during or after the injection.
- Maintain supporting clinical evidence justifying the use of this specific biosimilar agent.
- Record the provider’s credentials and signature verifying the injection and documentation accuracy.
## **Q5128 billing requirements**
When submitting claims, ensure billing documentation meets payer and regulatory requirements by including the following key elements:
- Use HCPCS code Q5128 for billing the injection of ranibizumab eqrn Cimerli biosimilar 0.1 mg.
- Billing frequency should align with the approved treatment regimen and payer-specific limits; typically, this involves dosing units based on 0.1 mg per unit administered.
- Include the appropriate modifiers as required by the payer, such as modifiers for laterality or bilateral procedures if applicable.
- Ensure medical necessity documentation supports the billing, including diagnoses related to conditions like diabetic macular edema and other retinal diseases targeted by VEGF A inhibition.
- Coverage varies by payer; verify patient insurance and authorization requirements before billing.
- Report the procedure alongside CPT code 67028 for the intravitreal injection of a pharmacologic agent, as this distinguishes the drug administration from the injection procedure itself.
## **Other relevant codes**
- J2778: Injection, ranibizumab, 0.1 mg
- J2779: Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
- 67028: Intravitreal injection of a pharmacologic agent
Frequently asked questions
